Company to host conference call on Wednesday, March 17 at 8:30 am EST · First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation · Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust
